Study of Efficacy and Safety of Secukinumab in Participants With Moderate-severe Rotator Cuff Tendinopathy

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2023
The purpose of the present study is to assess the efficacy of secukinumab 300 mg s.c. (subcutaneous) compared to placebo, each in combination with standard of care, in improving signs, symptoms and physical function in participants with moderate to severe rotator cuff tendinopathy (RCT), using a randomized, double-blind, placebo controlled, parallel group design to minimize bias.
Epistemonikos ID: 5558385bb0b07c9f24d5531ceaef0cb9836c7974
First added on: Feb 19, 2024